The concept of utilizing
the immune system for the treatment of cancer has been tried for some time
without any direct breakthrough succes. So far "passive" immunotherapy
has experienced most success, with antibody and cytokine therapy leading the
way. There are, however, two cell therapies on the market utilizing a tumor
antigen strategy. The cell therapy approach has so far been limited to the
treatment of patients with melanoma and colorectal cancer. Corixa's cell therapy
Melacine is based on the "cell vaccine" concept and consists of lysed
(broken) cells from two human melanoma cell lines combined with Detox adjuvant.
Melacine is marketed by Schering-Plough. Intracell's cell therapy OncoVAX is
currently marketed in the Netherlands. This is an autologous vaccine designed to
provoke a specific immune response against colorectal cancer cells. Other cancer
vaccine strategies that are on the way include Actimmune, Allovectin-7, Avicine,
BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Ovarex, Oncophage, Osidem
and. These treatments are all close to FDA approval or in late stage clinical
trails.
"Novel Tumor Vaccine Approaches" is an
extensive description and analysis of industry activities in the field of cancer
vaccines. BioSeeker Group has identified over 200 industry related R&D
projects utilizing a tumor antigen strategy for anticancer immune stimulation.
These projects have been grouped into four main categories - "pure"
antigens or biological drugs, cell therapies, anti-idiotypic antibodies and gene
therapies. BioSeeker is also providing in-depth knowledge of industry efforts in
tumor antigen discovery, delivery, and presentation; as well as different
techniques for improving the immune response.
There are many theoretical advantages with the
cancer vaccine approach. If it works properly, both the primary tumor as well as
metastases can be treated. Further, the potential of a cancer vaccine to prevent
recurrences is a very important advantage. Developing a cancer vaccine that can
slow down or stop the disease progress without any significant side-effects
would still be a good start.
This 250+ page report is a close to complete
description of the ongoing efforts to develop innovative vaccines for the
treatment of cancer. The report identifies trends, describes and analyzes
strategic shifts made by the industry. It also serves as a guide and a
foundation for your needs of information structure. The comparison of
therapeutic strategies, targets and cancer indications reveals differences
between disease and treatment. Conference information from the latest meeting
held by the American Society of Clinical Oncology, the American Association
Cancer Research and the American Society of Hematology is also included in this
extensive analysis.
BioSeeker Group has recognized the need for
deeper analytical reports. Our Industry Activity Reports analyze activities with
large impact on R&D and market trends. Our Industry Activity Reports, focus
on different segments of the industry and follows and identifies important
activities.
It is almost impossible to keep up with the
enormous amount of information that we continuously are exposed to. It gets
worse when you want to structure and analyze it.
Through the continuous surveillance of more than
10,000 life science companies worldwide, BioSeeker Group analyses activities in
biotechnology and pharmaceutical industry. Sophisticated information management
in combination with highly educated analysts with extensive experience in
business intelligence builds a strong platform for producing valuable analytical
documents.
These reports will allow you to:
identify and follow trends and future insights
plan strategically
identify key breakthroughs important for your
company
get smarter in a tougher competition
exploit our independent analysis
track cutting edge companies, therapies and new
technologies
save significant time in identifying your
partners & competitor
Publication date: Sept. 9 2003
Price: $1950 (PDF), $2000 (Hardcopy)
Size: 256 pages
